Mekonos Raises $4.6M – New Capital & Expertise Will Accelerate Development of the Company’s Chip (SoC) & Commercial Partnerships

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

November 23, 2020

Mekonos, a biotech company launching the first-of-its-kind system-on-a-chip (SoC) for targeted ex vivo gene engineering, today announced it has completed a $4.6 million financing round.

Mekonos will use the new capital to accelerate the SoC platform for its current and new commercial partnerships. The SoC platform, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The platform is scalable across all cell types and has shown to be a high yield solution for partners. The platform helps companies increase capacity, accelerate discoveries, and develop new pre-clinical assets in the emerging cell and gene therapy space.

The financing round was led by Novartis AG with participation from institutional VCs including Hike Ventures, CRCM Ventures. Existing investors participated in the round, including Good AI Capital and previous lead Elementum Ventures.

“We are delighted to work with such a strong team of investors and advisors who share our vision for the future of molecular delivery, gene therapies, and synthetic biology. This financing follows exciting momentum from the past year, including ongoing collaborations with two top 5 pharma companies and cell therapy research groups for our high yield SoC molecular delivery,” said Anil Narasimha, Ph.D., Co-Founder and CEO, Mekonos.

The company recently completed pilots with key top pharmaceutical companies and research institutes that demonstrated high efficacy of modified gene expression and cell viability. They are now preparing to expand existing partnerships and engage in new ones.

Mekonos’ platform is a physically controlled infrastructure that removes statistical uncertainty so that therapy cells are controlled like data. A scalable gene-editing chip constitutes the core of such a platform. Thanks to the recent combination of commercialized innovations, the vision of applying advanced semiconductor manufacturing technology to the production of disposable chips capable of editing the genes of millions of cells in parallel would have been unthinkable a few years ago. Bringing such scale to the application space of advanced therapies would allow for an unmatched level of automation, quality, precision, and agility from other existing technologies.

“The Mekonos technology represents a highly innovative non-viral gene delivery method that can benefit all cell therapy modalities,” said Dr. Cassian Yee, Director of Solid Tumor Cell Therapy, who recently joined Dr. Carolyn Bertozzi, Director, ChEM-H, and Dr. Irv Weissman, Director, Institute for Stem Cell Biology and Regenerative Medicine on the scientific advisory board of the company.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.